Archive | October, 2009
Opko Health’s New Acquisition (AMEX:OPK)
Formerly known as Ophthalmic Technologies Inc. Opko Health has recently agreed to acquire Chilean pharmaceutical company named Pharma Genexx for around US$ 16 million in cash. One of the reasons why this Florida-based pharma giant is taking up Chilean pharmaceutical is to enter the emerging markets in the future. The Miami-based Opko Health is a [...]
Continue reading...GSK faces new delays (NYSE:GSK)
2 October 2009 – 7:00 am PST
Comments Off
GSK, one of the top pharmaceutical companies, is facing new delays over the approval of their vaccine Cervarix that is aimed for the treatment of cervical cancers. GSK said that the reason for delay is because the FDA failed to complete their review on Cervarix by the anticipated deadline. However, soon GSK was dragged into [...]
Continue reading...Catalyst shares on rise (NASDAQ:CPRX)
2 October 2009 – 6:30 am PST
Comments Off
October 1st 2009 brought good news to Catalyst Pharmaceutical Partners when they decided to continue with the development of their addiction drug. It was announced that even though they had failed earlier they will still continue with the clinical development of their drug and as soon as the news was out, shares of Catalyst Pharmaceutical [...]
Continue reading...Caraco reaches agreement with FDA panel (AMEX: CPD)
2 October 2009 – 6:00 am PST
Comments Off
Caraco Pharmaceuticals, an US-based subsidiary of Sun Pharma has agreed to go through a series of actions as per the requirements of the Food and Drug Administration of the United States of America after which the FDA would lift their ban on certain manufacturing units of Caraco Pharmaceuticals. The voluntary agreement was reached between the [...]
Continue reading...Should There Be a Credit Card in Your Future VISA
2 October 2009 – 5:30 am PST
Comments Off
Your credit score affects more than just whether you’ll be granted a loan, mortgage or credit card. Insurance companies look at the score as a measure of responsibility. You may pay higher premiums for auto insurance for example if your credit score is lower than someone who has good credit.  Employers review credit reports as [...]
Continue reading...Sanofi-Aventis’ New Deals (NYSE:SNY)
2 October 2009 – 5:00 am PST
Comments Off
Though Sanofi-Aventis have been talking about their big pharma plans, it was today when they announced about their new billion-dollar plans. The company today announced their plans to acquire France’s Fovea Pharmaceuticals and MA-based Merrimack Pharmaceuticals for around US$ 530 million. Sanofi-Aventis announced that are all ready and prepared to spend the mentioned amount to [...]
Continue reading...Only news is bad news
1 October 2009 – 2:36 pm PST
Comments Off
In these days of Debbie Downers and Negative Neds it’s hard to keep a positive outlook, especially in the financial arena. It seems like we should all throw in the towel and slide from what is possibly the end of a recession to the depths of a depression. Don’t let that become a self fulfilling [...]
Continue reading...Chelsea Therapeutics Rallies on Droxidopa Data (NASDAQ:CHTP)
1 October 2009 – 2:32 pm PST
Comments Off
Chelsea Therapeutics International (NASDAQ:CHTP) said its drug Droxidopa has a benefit for five neurological disorder symptoms. CHTP will continue to further investigate these benefits even though last week Chelsea announced the drug did not meet its primary endpoints of the trial. Blame this failure to meet the primary endpoints on a poor trial design and the [...]
Continue reading...ImmunoCellular Therapeutics Delivers on Key Milestones (OTC:IMUC)
1 October 2009 – 12:28 pm PST
Comments Off
ImmunoCellular just announced their lead monoclonal antibody product candidates ICT-109 had positive result in their lead study of detecting cancerous tissues. The results were statically significant suggesting that this antibody can determine if tissues are cancerous or non-cancerous in plasma and serum study sets. These results from the study lead IMUC to believe that this ICT-109 molecule can play an important [...]
Continue reading...Vertex strapped for cash (NASDAQ:VRTX)
1 October 2009 – 10:16 am PST
Comments Off
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) sold the rights to its key milestone payments for their hepatitis C drug in development telaprevir, worth up to $95 million. VRTX also raised $155 million by issuing new issuing notes due in 10/31/2012. It sounds like the company needed money fast, and thats exactly the news VRTX came out with next to [...]
Continue reading...
5 October 2009 – 5:00 am PST
Comments Off